^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microtubule inhibitor

    Related drugs:
    21h
    COSTA: A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Cristiana Costa Chase, DO | Trial completion date: Oct 2027 --> Jun 2028 | Trial primary completion date: Oct 2025 --> May 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Blenrep (belantamab mafodotin-blmf)
    21h
    A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Memorial Sloan Kettering Cancer Center
    New trial
    |
    Padcev (enfortumab vedotin-ejfv)
    1d
    Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=20 --> 4
    Enrollment closed • Enrollment change • Minimal residual disease
    |
    lenalidomide • Blenrep (belantamab mafodotin-blmf)
    2d
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. (clinicaltrials.gov)
    P3, N=752, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    HER-2 negative • HER-2 expression • CLDN18.2 positive • CLDN1 positive
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • tecotabart vedotin (LM-302)
    3d
    Case Report: Personalized management of HER2-positive breast cancer with advanced nodal disease during pregnancy: a clinical case and review. (PubMed, Front Oncol)
    The patient subsequently received adjuvant chest wall and nodal region radiotherapy plus trastuzumab-emtansine (T-DM1). This case underscores the value of personalized, multidisciplinary management in PrBC, particularly in patients with high-risk biologic features and advanced nodal disease. Integrating clinical judgment, genomic tools, and adaptive strategies, while accounting for gestational limitations, can optimize oncologic outcomes without compromising fetal safety.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    HER2DX
    |
    Kadcyla (ado-trastuzumab emtansine)
    3d
    Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL. (PubMed, Blood Rev)
    Recently, ADCs have expanded the DLBCL therapeutic landscape, with the approvals of CD79b-targeted polatuzumab vedotin and CD19-directed loncastuximab tesirine for R/R and even frontline disease. However, the clinical application of ADCs is accompanied by challenges, including the management of characteristic toxicities, understanding and overcoming mechanisms of resistance. This review systematically synthesizes the mechanisms of action, updated clinical evidence, toxicity profiles, and resistance mechanisms of ADCs in DLBCL, while also discusses management strategies and provides perspectives on future directions.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule)
    |
    Rituxan (rituximab) • Zynlonta (loncastuximab tesirine-lpyl) • Polivy (polatuzumab vedotin-piiq)
    3d
    Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=62, Recruiting, Mayo Clinic | Trial completion date: May 2027 --> Jun 2034 | Trial primary completion date: May 2026 --> Jun 2029
    Trial completion date • Trial primary completion date
    |
    Blenrep (belantamab mafodotin-blmf)
    4d
    MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, West China Hospital
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    4d
    Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=84, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Adcetris (brentuximab vedotin) • dexamethasone
    5d
    Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=69, Recruiting, Oncomatryx Biopharma S.L.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • OMTX705